JGC
INFI

J. Goldman & Co’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

J. Goldman & Co’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-517,500
Closed -$1.55M – 501
2021
Q2 		$1.55M Sell
517,500
-468,638
-48% -$1.48M 0.06% 251
2021
Q1 		$3.19M Buy
+986,138
New +$3.29M 0.1% 207

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

J. Goldman & Co's INFI Position: Q3 2021 in Review

J. Goldman & Co sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2021, closing a stake of 517,500 shares — an estimated $1.55M sold.

J. Goldman & Co first reported a position in INFI in Q1 2021 and held it in 2 quarters. The position peaked at $3.19M in Q1 2021. 107 funds tracked by Wall St. Rank hold INFI as of Q3 2021.

  • J. Goldman & Co reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • J. Goldman & Co sold 517,500 Infinity Pharmaceuticals, Inc. shares in Q3 2021, an estimated $1.55M.
  • J. Goldman & Co first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2021 and held it in 2 quarters.
  • J. Goldman & Co's Infinity Pharmaceuticals, Inc. position peaked at $3.19M in Q1 2021.
  • 107 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2021.

Based on J. Goldman & Co's 13F filing for Q3 2021, filed 15 Nov 2021.